Amishi Shah, M.D.
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2010 | Baylor College of Medicine, Houston, TX, USA, MD, Medicine |
| 2006 | Rice University, Houston, TX, USA, BS, Biochemistry and Cell Biology |
Postgraduate Training
| 2013-2016 | Clinical Fellowship, MD Anderson Cancer Center, Houston, TX |
| 2011-2013 | Clinical Residency, University of Pennsylvania, Philadelphia, PA |
| 2010-2011 | Clinical Internship, University of Pennsylvania, Philadelphia, PA |
Board Certifications
| 2016 | American Board of Internal Medicine Hematology |
| 2013 | American Board of Internal Medicine |
Experience & Service
Other Appointments/Responsibilities
Chief Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2016
Chief Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2015
Institutional Committee Activities
Committee Member, Clinical Research Committee #1, 2016 - 2019
Committee Member, Update on Management of GU Malignancies Yearly Conference, 2016 - 2019
Committee Member, Hematology - Medical Oncology Fellowship Steering Committee, MDACC, 2014 - Present
Honors & Awards
| 2019 | 4th Annual APRN Fellows' Choice Award for Outstanding Faculty Preceptor, MD Anderson Cancer Center |
| 2019 | 2019 Top Performer – Top 10% Nationally in CAHPS, MD Anderson Cancer Center |
| 2018 | Teaching Dept of the Year for Hem-Onc Program, MD Anderson Cancer Center |
| 2017 | Nationally Recognized in the Top 1 Percentile on CAHPS scores, MD Anderson Cancer Center |
| 2017 | Teaching Dept of the Year for Hem-Onc Program, MD Anderson Cancer Center |
| 2015 | 2nd Year Fellow of the Year Award, LBJ Hospital, MD Anderson Cancer Center |
| 2015 | Fellows Recognition Program Nomination, NCCN Annual Conference |
| 2014 | Clifton D. Howe Award for Clinical Excellence, MD Anderson Cancer Center |
| 2013 | Conquer Cancer Foundation Merit Award, American Society of Clinical Oncology |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Campbell MT, Bilen MA, Shah AY, Lemke E, Jonasch E, Venkatesan AM, Altinmakas E, Duran C, Msaouel P, Tannir NM. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. Eur J Cancer 104:188-194, 2018. e-Pub 2018. PMID: 30380460.
- Flannery K, Cao X, He J, Zhong Y, Shah AY, Kamat AM. Survival Rates and Health Care Costs for Patients with Advanced Bladder Cancer Treated and Untreated with Chemotherapy. Clin Genitourin Cancer 16(4):e909-e917, 2018. e-Pub 2018. PMID: 29735397.
- Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int 120(6):782-792, 2017. e-Pub 2016. PMID: 27860149.
- Kamat AM, Cao X, He J, Zhong Y, Shah AY, Flannery K. Costs of Care for Patients Receiving Chemotherapy for Advanced Bladder Cancer. Journal of Clinical Pathways, 2017.
- Shah AY, Tannir NM. Editorial Comment. Urology 109:132, 2017. e-Pub 2017. PMID: 28867144.
- Shah AY, Gao J, Siefker-Radtke AO. Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer. Immunotherapy 9(10):781-784, 2017. PMID: 28877627.
- Campbell MT, Shah AY, Matin SF, Siefker-Radtke AO. Optimizing management of upper tract urothelial carcinoma. Urol Oncol 35(7):492-498, 2017. e-Pub 2017. PMID: 28579283.
- Malouf GG, Joseph RW, Shah AY, Tannir NM. Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities. Clin Adv Hematol Oncol 15(5):409-418, 2017. PMID: 28591094.
- Shah AY, Karam JA, Lim ZD, Ng CS, Tannir NM. Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mRCC) treated with sunitinib: Is mRCC curable with targeted therapy?. Urol Case Rep 3(2):18-20, 2015. PMID: 26120560.
- Shah AY, Doherty SD, Rosen T. Actinic cheilitis: a treatment review. Int J Dermatol 49(11):1225-34, 2010. PMID: 20964646.
- Alhalabi O, Shah AY, Lemke EA, Gao J. Current and Future Landscape of Immunotherapy in Urothelial Cancer. ONCOLOGY.
- Campbell MT, Bilen MA, Duran C, Altinmakas E, Lim Z, Shah AY, Jonasch E, Tannir N. Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma (vhRCC): A retrospective analysis. European Journal of Cancer.
- Lewis GD, Jonasch E, Shah AY, Fuller GN, Farach AM, Butler EB, Teh BS. Renal cell carcinoma brain metastasis with pseudoprogression and 4 radiation necrosis on nivolumab after previous treatment with 5 stereotactic radiosurgery: An illustrative case report and review of the 6 literature. Practical Radiation Oncology.
- Chahoud J, Zhang M, Shah AY, Lin SH, Pisters LL, Tu SM. Managing seminomatous and nonseminomatous germ cell tumors. Curr Opin Oncol. e-Pub 2018. PMID: 29538040.
- Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AY. Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clin Genitourin Cancer. e-Pub 2017. PMID: 28870517.
- Shah AY, Karam JA, Malouf G, Rao P, Lim Z, Jonasch E, Xiao L, Gao JJ, Vaishampayan U, Heng DY, Plimack E, Guancial E, Fung C, Lowas S, Tamboli P, Sircar K, Matin S, Rathmell K, Wood CG, Tannir NM. Management and Outcome of Patients with Renal Medullary Carcinoma: A Multi-Center Collaborative Study. BJU International. e-Pub 2016.
Invited Articles
- Nirvana da Cruz-Formiga M, Shah AY. Adjuvant & Neoadjuvant Therapy of Bladder Cancer. Oncology Times, 2017.
Manuals, Teaching Aids, Other Teaching Publications
- Shah AY. BMJ Best Practice Guidelines: Renal Cell Carcinoma, 2017.
Editorials
- Shah AY, Tannir NM. Surveillance or Systemic Therapy? An Editorial Re: Observation After Cytoreductive Nephrectomy in Patients with Synchronous not Completely Resected Metastases of Renal Cell Carcinoma. The Journal of Urology.
- Shah AY, Gao JJ, SIefker-Radtke AO. Five New Therapies or Just 1 New Treatment? A Crticial Look at Immune Checkpoint Inhibition in Urothelial Cancer. The Journal of Immunology.
Abstracts
- Shah AY, Lemke EA, Gao J, Chandamohan A, Campbell MT, Zurita A, Xiao L, Wang J, Corn PG, Jonasch E, Sharma P, Tannir N. Outcomes of patients (pts) with metastatic clear-cell renal cell carcinoma (mCCRCC) treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitors (ICI). 2018 Genitourinary Cancers Symposium, 2018.
- Lemke EA, Shah AY, Campbell MT, Tannir NM. Real-world experience with cabozantinib in metastatic clear cell renal cell carcinoma (mccRCC). 2018 Genitourinary Cancers Symposium, 2018.
- Lemke EA, Shah AY, Campbell MT, Tannir NM. Comparing cabozantinib (C) treatment for a cohort of patients with metastatic clear cell (ccRCC) and variant histology renal cell carcinoma (vhRCC): A retrospective study. 2018 Genitourinary Cancers Symposium, 2018.
- Campbell M, Shah AY, Matin S, Siefker-Radtke AO. Optimizing management of upper tract urothelial carcinoma. Urologic Oncology, 2017.
- Shay AY, Lemke EA, Gao J, Chandramohan A, Campbell MT, Zurita AJ, Xiao L, Wang J, Corn PG, JOnasch E, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma (mRCC) who were treated with second-line (2L) vascular endothelial growth receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitor (ICI) therapy. ESMO 2017 Abstract Book 28, 2017.
- Flannery K, Cao X, He J, Zhong Y, Shah AY, Kamat A. Real World Treatment Costs and Resource Utilization among Patients with Metastatic Bladder Cancer. European Society for Medical Oncology.
- Campbell MT, Asim Bilen M. Duran C, Altinmakas E, Lim Z, Shah A, Jonasch E, Tannir NM. Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma (vhRCC): a retrospective study. European Society for Medical Oncology.
- Shah AY, Gao J, Lemke ES, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Sharma P, Tannir NM. Responses to second-line tyrosine kinase inhibitors after first-line immune checkpoint inhibitors in advanced renal cell carcinoma. American Society of Clinical Oncology - ASCO.
- Tannir NM, Campbell MT, Pant S, Fu S, Colen R, Painter J, Banerjee U, Khan S, Lim ZD, Patel AB, McQuinn L, Stephen B, Gong J, Mendoza T, Hess K, Meric-Bernstam F, Nain A. Phase ll Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients with Renal Medullary Carcinoma. American Society of Clinical Oncology - ASCO.
- Wang J, Araujo J, Tu SM, Campbell MT, Shah AY, Shubham P, Fu Si, Colen R, Painter J, Tsimberidou A, Karp D, Patel AB, Mendoza T, Hess K, Meric-Bernstam F, Naing A. Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients with Penile Carcinoma. American Society of Clinical Oncology - ASCO.